GRAL · GRAIL, Inc.
Market Cap
$3.59B
Shares
44.67M
GRAL metrics
59 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$80.56
Market cap
$3.59B
Price action
19 metricsPrice change (1W)
-3.3%
Price change (30D)
+13.5%
Price change (3M)
+33.2%
Price change (6M)
+51.2%
Price change (YTD)
-6.8%
Price change (1Y)
+143.3%
Trailing year
Price change (5Y)
—
52-week high
$116.06
52-week low
$31.61
Change from 52-week high
-31.3%
Change from 52-week low
+152.4%
Annualized volatility
100.7%
Beta
2.7
RSI (14D)
57.5
Price vs SMA 50
+11.6%
Price vs SMA 200
+9.0%
Avg volume (3M)
667,823
Relative volume
0.7
Average dollar volume
$45.93M
Company
3 metricsSector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
44.67M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
21.7×
reciprocal yield 4.6%
P / book
1.4
reciprocal yield 70.8%
FCF yield
-8.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-05
Profitability
9 metricsGross margin
—
Operating margin
-338.4%
Trailing 12 months
Net margin
-236.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$559.25M
Net income (TTM)
−$391.59M
Trailing 12 months
Diluted EPS (TTM)
$-9.68
FCF margin
-179.2%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+25.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$165.26M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+20.4%
Year over year · more shares
Revenue CAGR (3Y)
+38.4%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-15.4%
Return on assets
-13.8%
Debt / equity
—
Current ratio
10.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$296.16M
Quick ratio
10.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$55.65M
Latest balance sheet
Cash & equivalents
$55.65M
Total assets
$2.84B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$294.75M
Capital expenditures (TTM)
$1.41M
R&D (TTM)
$190.99M
SG&A (TTM)
—
Stock compensation (TTM)
$64.25M
R&D / revenue
115.6%
Stock compensation / revenue
38.9%
Ownership (13F)
3 metrics13F filers
379
13F filer change QoQ
+7
Institutional ownership
89.3%
Short interest
3 metricsShort interest
18.3%
Latest settlement · 9.8 days to cover
Days to cover
9.8d
Short-squeeze score
86 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.10M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
277 filings
270 filers
Visit website
Investor relations